• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.

作者信息

Zheng Hong, Mineishi Shin, Claxton David, Zhu Junjia, Zhao Chenchen, Jia Bei, Ehmann W Christopher, Rybka Witold B, Naik Seema, Songdej Natthapol, Drabick Joseph J, Hohl Raymond J

机构信息

Penn State Cancer Institute, Penn State University College of Medicine, Hershey, Pennsylvania, USA.

Department of Public Health Sciences, Penn State University College of Medicine, Hershey, Pennsylvania, USA.

出版信息

Am J Hematol. 2021 Feb 1;96(2):E46-E50. doi: 10.1002/ajh.26043. Epub 2020 Nov 23.

DOI:10.1002/ajh.26043
PMID:33146922
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7894154/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/7894154/e08dc02a7266/AJH-96-E46-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/7894154/e08dc02a7266/AJH-96-E46-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/543c/7894154/e08dc02a7266/AJH-96-E46-g001.jpg

相似文献

1
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.一项avelumab联合地西他滨作为不适合进行一线治疗的急性髓系白血病患者的I期临床试验。
Am J Hematol. 2021 Feb 1;96(2):E46-E50. doi: 10.1002/ajh.26043. Epub 2020 Nov 23.
2
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.地西他滨与强化化疗治疗新诊断的老年急性髓系白血病患者的比较
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):290-299.e3. doi: 10.1016/j.clml.2019.02.002. Epub 2019 Feb 20.
3
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.塔拉唑单抗联合地西他滨或地西他滨单独治疗不适合化疗的急性髓系白血病患者的安全性和有效性：来自多中心、随机、2/3 期研究的结果。
Leukemia. 2021 Jan;35(1):62-74. doi: 10.1038/s41375-020-0773-5. Epub 2020 Mar 16.
4
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML.一项在 CD33 阳性 AML 患者中联合使用 vadastuximab talirine 和低甲基化药物的 1 期临床试验。
Blood. 2018 Sep 13;132(11):1125-1133. doi: 10.1182/blood-2018-03-841171. Epub 2018 Jul 25.
5
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.为不适合强化治疗的老年新诊断 AML 患者寻找最佳联合治疗方案。
Leuk Res. 2015 Feb;39(2):183-91. doi: 10.1016/j.leukres.2014.11.027. Epub 2014 Dec 9.
6
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.地西他滨与吉妥珠单抗奥唑米星用于新诊断及复发的急性髓系白血病和高危骨髓增生异常综合征的II期研究。
Leukemia. 2016 Feb;30(2):268-73. doi: 10.1038/leu.2015.244. Epub 2015 Sep 14.
7
Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.地西他滨、伊达比星、阿糖胞苷和粒细胞集落刺激因子联合（DIAG）方案治疗高危骨髓增生异常综合征和急性髓系白血病。
Ann Hematol. 2019 Sep;98(9):2223-2225. doi: 10.1007/s00277-019-03674-2. Epub 2019 Apr 12.
8
Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.地西他滨诱导化疗后血小板计数的早期恢复是老年新发急性髓系白血病患者对治疗反应良好的预后标志物。
BMC Cancer. 2018 Dec 19;18(1):1269. doi: 10.1186/s12885-018-5160-5.
9
Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.微小残留病可能是接受基于地西他滨的化疗诱导的新诊断急性髓系白血病患者的早期预后指标。
Hematology. 2019 Dec;24(1):552-558. doi: 10.1080/16078454.2019.1642552.
10
Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病
Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.

引用本文的文献

1
Bone marrow immune cells and drug resistance in acute myeloid leukemia.急性髓系白血病中的骨髓免疫细胞与耐药性
Exp Biol Med (Maywood). 2025 Feb 11;250:10235. doi: 10.3389/ebm.2025.10235. eCollection 2025.
2
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML.CD36 依赖性非经典脂质代谢程序促进 AML 中的免疫逃逸和对低甲基化剂治疗的耐药性。
Cell Rep Med. 2024 Jun 18;5(6):101592. doi: 10.1016/j.xcrm.2024.101592. Epub 2024 Jun 5.
3
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.

本文引用的文献

1
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.癌症治疗中的免疫检查点靶向治疗：迈向具有治愈潜力的联合策略。
Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030.
2
Immune checkpoint blockade: a common denominator approach to cancer therapy.免疫检查点阻断：癌症治疗的一种通用方法。
Cancer Cell. 2015 Apr 13;27(4):450-61. doi: 10.1016/j.ccell.2015.03.001. Epub 2015 Apr 6.
3
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
用于急性髓系白血病的单克隆抗体免疫疗法：一项正在进行的工作。
Cancers (Basel). 2023 Oct 19;15(20):5060. doi: 10.3390/cancers15205060.
4
Progress of research on PD-1/PD-L1 in leukemia.PD-1/PD-L1 在白血病中研究进展。
Front Immunol. 2023 Sep 26;14:1265299. doi: 10.3389/fimmu.2023.1265299. eCollection 2023.
5
STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia.STAT5 通过促进组蛋白乳酰化促进 PD-L1 表达，从而驱动急性髓系白血病中的免疫抑制。
Signal Transduct Target Ther. 2023 Sep 30;8(1):391. doi: 10.1038/s41392-023-01605-2.
6
The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients.免疫检查点蛋白与急性髓系白血病患者治疗结果之间的关联
Cancers (Basel). 2023 Sep 9;15(18):4487. doi: 10.3390/cancers15184487.
7
Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.利用急性髓细胞白血病中的自体免疫效应机制：试验与困境的 2023 年更新。
Leuk Res. 2023 Nov;134:107388. doi: 10.1016/j.leukres.2023.107388. Epub 2023 Sep 14.
8
CD26PD-1 CD8 T cells are terminally exhausted and associated with leukemia progression in acute myeloid leukemia.CD26PD-1 CD8 T 细胞衰竭终末期，并与急性髓系白血病中的白血病进展相关。
Front Immunol. 2023 Jun 29;14:1169144. doi: 10.3389/fimmu.2023.1169144. eCollection 2023.
9
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.急性髓系白血病免疫治疗的前景：当前进展与挑战
Front Pharmacol. 2023 Apr 19;14:1151032. doi: 10.3389/fphar.2023.1151032. eCollection 2023.
10
Targeted therapy in NPM1-mutated AML: Knowns and unknowns.NPM1 突变型急性髓系白血病的靶向治疗：已知与未知
Front Oncol. 2022 Sep 27;12:972606. doi: 10.3389/fonc.2022.972606. eCollection 2022.
阿扎胞苷导致骨髓增生异常综合征/急性髓系白血病患者T细胞中PD-1低甲基化及上调：联合靶向PD-1与DNA甲基化的理论依据
Oncotarget. 2015 Apr 20;6(11):9612-26. doi: 10.18632/oncotarget.3324.
4
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.低甲基化剂治疗可增强骨髓增生异常综合征中 PD-L1、PD-L2、PD-1 和 CTLA4 的表达。
Leukemia. 2014 Jun;28(6):1280-8. doi: 10.1038/leu.2013.355. Epub 2013 Nov 25.
5
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.多中心、随机、开放标签、III 期临床试验，比较地西他滨与患者选择的支持治疗或低剂量阿糖胞苷治疗新诊断的老年急性髓系白血病，患者选择方案由医生提供建议。
J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11.